Table 1 Companies exploring concepts for γδ T cell based immunotherapy
From: Cancer immunotherapy with γδ T cells: many paths ahead of us
Company | General strategy | Specific approach (if disclosed) | Web site |
|---|---|---|---|
Adicet Bio, Inc. | Allogeneic gene-modified γδ T cells* | CAR or TCR-modified γδ T cells | |
Cytomed Therapeutics | Allogeneic gene-modified γδ T cells* | CAR-modified (by mRNA electroporation) γδ T cells | |
Editas medicine | Gene-modified γδ T cells | Not disclosed | |
Gadeta | αβ T cells transduced with γδ TCR | High affinity Vγ9Vδ2 TCR (TEG) | |
GammaCell Biotechnologies | Expansion of Vγ9Vδ2T cells | ||
GammaDelta Therapeutics | Allogeneic blood and skin-derived Vδ1 γδ T cells | Unmodified or CAR | |
Immatics | Allogeneic gene-modified γδ T cells* | IMA301 Cancer testis antigen αβ TCR | |
Incysus Therapeutics | Drug-resistant γδ T cells allogeneic γδ T cells | Allogeneic unmodified γδ T cells • Phase I study in leukemia patients undergoing hematopoietc stem cell transplantation Drug-resistant γδ T cells • Phase I study in glioblastoma | |
Leucid Bio | CAR-modified γδ T cells | ||
PhosphoGam Inc. | Allogeneic Vδ2 T cell transfer* | Off-the-shelf, selection of suitable donor-patient combinations | |
TC Biopharm | Allogeneic γδ T cell transfer* | • Unmodified or CAR modified TCB002 OmnImmune phase I (allogeneic unmodified γδ in AML) | |
Adaptate Biotherapeutics | Modulate γd T cell activation in situ with antibodies | Spin-off of GammaDelta Therapeutics | |
American Gene Technologies | Transduce danger signal to tumor to activate γδ T cells in situ | 3rd generation lentiviral vector, tumor cells then activate Vδ2 γδ T cells | |
ImCheck Therapeutics | Targeting Vγ9Vδ2T cells in vivo | • Agonistic anti-BTN3A antibody: ICT01 (EVICTION Trial phase I/IIa) • Antagonistic anti-BTN3A antibody: ICT21 (autoimmune diseases) | |
Lava Therapeutics | Targeting Vγ9Vδ2 T cells in vivo | Bispecific Vγ9Vδ2 T cell engagers targeting γδ T cells to tumor-expressed antigens | |
PureTech Health PLC | Targeting immunosuppressive Vδ1T cells in vivo | Human anti-Vδ1 antibody LYT-210 |
